#### Docket No. 103864.1101RJ

PATENT

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Reissue Application of

Christopher J. LASHER, et al.

Confirmation No.: 5298

Scrial No. 09/512,734

Group Art Unit: 3721

Filed: February 24, 2000

Examiner: SIPOS, J.

For: Enhanced Drug Dispensing System

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

### AMENDMENT TRANSMITTAL

Transmitted herewith is an Amendment in the above identified application.

No additional fee is required.

Also attached: Request for Continued Examination Transmittal; Petition for Extension of Time; Assignce's Consent to Reissue; Applicant Initiated Interview Request Form Consent to Reissue; Statement Under 37 C.F.R. 3.73(b)..

[X] The fee has been calculated as shown below:

	NO. OF CLAIMS	HIGHEST PREVIOUSLY PAID FOR	EXTRA CLAIMS	RATE	FEE
Total Claims				x \$50 ==	
Independent Claims				x \$200 -	
		If multiple claims newly presented, add \$290.00			
	Petition for Extension of Time				\$570.00
		TOTAL FEE DUE			\$570.00

- [X] Please charge my Deposit Account No. 08-0219 in the amount of \$450.00.
- [X] The Commissioner is hereby authorized to charge payment of any fees associated with this communication or credit any overpayment, to Deposit Account No. <u>08-0219</u>, including any filing fees under 37 CFR 1.16 for presentation of extra claims and any patent application processing fees under 37 CFR 1.17.

Respectfully submitted,

Wilmer Cutler Pickering Hale and Dorr LLP

Iran II. Donne

Registration No. 35,120

Date: 7/5

399 Park Avenue

New York, NY 10022

Phone: (212) 230-8800 Fax: (212) 230-8888

USIDOCS 5183539v1

# RECEIVED CENTRAL FAX CENTER JUL 0 5 2005

Attorney Docket No. 103864.1101

**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Reissue Application of

Christopher J. LASHER, et al.

Serial No. 09/512,734

Filed: February 24, 2000

For: Enhanced Drug Dispensing System

Confirmation No.: 5298

Group Art Unit: 3721

Examiner: J. Sipos

### AMENDMENT -

This is an Amendment accompanying a Request for Continued Examination filed concurrently herewith. Entry of the following amendments and favorable reconsideration is respectfully requested in view of the following remarks.

Amendments to the Claims begin on page 2 of this paper.

Remarks begin on page 35 of this paper.

Conclusion begins on page 52 of this paper.

Authorization begins on page 55 of this paper.